...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Response- clear as mud imo

My two cents, I don't think they could really tell us anything if they were negotiating anything important (which allows management to hide behind that some what). I totally agree that especially with their track record that management should be much more forth coming with details re Cencora.  I find they behave with an attitude as if they had a track record of multiple successes and a history of accomplishing what they say they are going to accomplish. Clearly neither of which is true. I truly wish they would start earning their keep so to speak and actually accomplish something. The exception to the above I suspect is Sanjay Lakothia whom again I suspect is the reason for Zenith's involvement in multiple trials. Certainly a brighter spot and a huge difference from RVX in that regard. 

Koo, I find the reply to your inquiry an interesting CYA as to my way of thinking the only truly independent director in the whole mix is Brad Thompson the rest have, to me, interests that are somewhat intertwined  JMO

 

Share
New Message
Please login to post a reply